Work

Cytoprotective Palifermin Allowed Melphalan Dose Escalation to 280mg/2 for Multiple Myeloma Patients with Normal Renal Function Receiving Autologous Stem Cell Transplantation (ASCT) - Final Results of a Phase 1 Trial

Year: 2010

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v116.21.2401.2401

Authors: Muneer H. Abidi, Nishant Tageja, Lawrence G. Lum, Judith Abrams, Zaid Al-Kadhimi, Lois Ayash, Simon Cronin, Marie Ventimiglia, Abhinav Deol, Voravit Ratanatharathorn, Joseph P. Uberti

Institutions: Wayne State University, The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2544608079

FWCI:

Cites:

Cited by:

Related to: 10